Molecular epidemiology and evolution of A(H1N1)pdm09 and H3N2 virus during winter 2012-2013 in Beijing, China

Infection, Genetics and Evolution

Volumn 26, Issue , 2014, Pages 228-240

  Fang, Qiongxuan ^a   Gao, Yan ^a   Chen, Meifang ^a   Guo, Xiaolin ^a   Yang, Xia ^a   Yang, Xiaohua ^b   Wei, Lai ^a  

^a PEKING UNIVERSITY   (China)

^b THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

Author keywords

A(H1N1)pdm09; H3N2; Molecular genetic analysis; Phylogeny

Indexed keywords

INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; OSELTAMIVIR; VIRUS SIALIDASE; NA PROTEIN, INFLUENZA A VIRUS; SIALIDASE; VIRUS PROTEIN; VIRUS RNA;

AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; ARTICLE; CHINA; CLADISTICS; CLINICAL ARTICLE; ENZYME ACTIVE SITE; GENETIC DRIFT; HUMAN; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H1N1 PDM09; INFLUENZA VIRUS A H3N2; MOLECULAR EPIDEMIOLOGY; MOLECULAR EVOLUTION; MOLECULAR PHYLOGENY; NONHUMAN; NUCLEOTIDE SEQUENCE; PHYLOGENETIC TREE; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; SEQUENCE ANALYSIS; SPECIES DISTRIBUTION; VIRUS CLASSIFICATION; VIRUS MUTATION; VIRUS STRAIN; VIRUS VIRULENCE; WINTER; CLASSIFICATION; DNA SEQUENCE; GENETICS; GENOTYPE; HISTORY; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H3N2); INFLUENZA, HUMAN; ISOLATION AND PURIFICATION; MOLECULAR GENETICS; MUTATION; PHYLOGENY; SEASON; VIROLOGY;

AMINO ACID SUBSTITUTION; EVOLUTION, MOLECULAR; GENOTYPE; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HISTORY, 21ST CENTURY; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA, HUMAN; MOLECULAR SEQUENCE DATA; MUTATION; NEURAMINIDASE; PHYLOGENY; RNA, VIRAL; SEASONS; SEQUENCE ANALYSIS, DNA; VIRAL PROTEINS;

EID: 84903216624     PISSN: 15671348     EISSN: 15677257     Source Type: Journal    
DOI: 10.1016/j.meegid.2014.05.034     Document Type: Article

References (39)

1. Air G.M. Influenza neuraminidase. Influenza Res. Viruses 2012, 6:245-256.
2. Chen J., Deng Y.-M. Influenza virus antigenic variation, host antibody production and new approach to control epidemics. Virol. J. 2009, 6:3.
3. Chen W., Zhong Y., Qin Y., Sun S., Li Z. The evolutionary pattern of glycosylation sites in influenza virus (H5N1) hemagglutinin and neuraminidase. PLoS ONE 2012, 7:e49224.
4. Cherry J.L., Lipman D.J., Nikolskaya A., Wolf Y.I. Evolutionary dynamics of N-glycosylation sites of influenza virus hemagglutinin. PLoS Curr. 2009, 1. 1: RRN1001.
5. Chutinimitkul S., Chieochansin T., Payungporn S., Samransamruajkit R., Hiranras T., Theamboonlers A., Poovorawan Y. Molecular characterization and phylogenetic analysis of H1N1 and H3N2 human influenza A viruses among infants and children in Thailand. Virus Res. 2008, 132:122-131.
6. CNIC Weekly Influenza Surveillance 2012.
7. CNIC Weekly Influenza Surveillance 2013.
8. Ghedin E., Sengamalay N.A., Shumway M., Zaborsky J., Feldblyum T., Subbu V., Spiro D.J., Sitz J., Koo H., Bolotov P. Large-scale sequencing of human influenza reveals the dynamic nature of viral genome evolution. Nature 2005, 437:1162-1166.
9. Graham M., Liang B., Van Domselaar G., Bastien N., Beaudoin C., Tyler S., Kaplen B., Landry E., Li Y. Nationwide molecular surveillance of pandemic H1N1 influenza A virus genomes: Canada, 2009. PLoS ONE 2011, 6:e16087.
10. Helenius A., Aebi M. Roles of N-linked glycans in the endoplasmic reticulum. Annu. Rev. Biochem. 2004, 73:1019-1049.
11. Hu W. Analysis of correlated mutations, stalk motifs, and phylogenetic relationship of the 2009 influenza A virus neuraminidase sequences. J. Biomed. Sci. Eng. 2009, 2:550-558.
12. Johansson B., Bucher D., Kilbourne E. Purified influenza virus hemagglutinin and neuraminidase are equivalent in stimulation of antibody response but induce contrasting types of immunity to infection. J. Virol. 1989, 63:1239-1246.
13. Kageyama T., Fujisaki S., Takashita E., Xu H., Yamada S., Uchida Y., Neumann G., Saito T., Kawaoka Y., Tashiro M. Genetic analysis of novel avian A(H7N9) influenza viruses isolated from patients in China, February to April 2013. Euro Surveill. 2013, 18:20453.
14. Kiso M., Mitamura K., Sakai-Tagawa Y., Shiraishi K., Kawakami C., Kimura K., Hayden F.G., Sugaya N., Kawaoka Y. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 2004, 364:759-765.
15. Kreijtz J., Fouchier R., Rimmelzwaan G. Immune responses to influenza virus infection. Virus Res. 2011, 162:19-30.
16. Langenhorst D., Gogishvili T., Ribechini E., Kneitz S., McPherson K., Lutz M.B., Hünig T. Molecular characterization of the predominant influenza A (H1N1) pdm09 virus in Mexico, December 2011-February 2012. PLoS ONE 2012, 7:e50116.
17. Lau L.L., Cowling B.J., Fang V.J., Chan K.-H., Lau E.H., Lipsitch M., Cheng C.K., Houck P.M., Uyeki T.M., Peiris J.M. Viral shedding and clinical illness in naturally acquired influenza virus infections. J. Infect. Dis. 2010, 201:1509-1516.
18. Liu D., Shi W., Shi Y., Wang D., Xiao H., Li W., Bi Y., Wu Y., Li X., Yan J. Origin and diversity of novel avian influenza A H7N9 viruses causing human infection: phylogenetic, structural, and coalescent analyses. Lancet 2013, 1(1).
19. Maurer-Stroh S., Ma J., Lee R.T., Sirota F.L., Eisenhaber F. Mapping the sequence mutations of the 2009 H1N1 influenza A virus neuraminidase relative to drug and antibody binding sites. Biol. Direct 2009, 4:18.
20. Mertens E., Dugan V.G., Stockwell T.B., Lindsay L.L., Plancarte M., Boyce W.M. Evaluation of phenotypic markers in full genome sequences of avian influenza isolates from California. Comp. Immunol. Microbiol. Infect. Dis. 2013, 36:521-536.
21. Munk K., Pritzer E., Kretzschmar E., Gutte B., Garten W., Klenk H.-D. Carbohydrate masking of an antigenic epitope of influenza virus haemagglutinin independent of oligosaccharide size. Glycobiology 1992, 2:233-240.
22. Neumann G., Noda T., Kawaoka Y. Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature 2009, 459:931-939.
23. Nguyen H.T., Fry A.M., Gubareva L.V. Neuraminidase inhibitor resistance in influenza viruses and laboratory testing methods. Antiviral Ther. 2012, 17:159.
24. Osterholm M.T., Kelley N.S., Sommer A., Belongia E.A. Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. Lancet Infect. Dis. 2012, 12:36-44.
25. Pariani E., Amendola A., Ebranati E., Ranghiero A., Lai A., Anselmi G., Zehender G., Zanetti A. Genetic drift influenza A (H3N2) virus hemagglutinin (HA) variants originated during the last pandemic turn out to be predominant in the 2011-2012 season in Northern Italy. Infect. Genet. Evol. 2013, 13:252-260.
26. Pebody R., Andrews N., McMenamin J., Durnall H., Ellis J., Thompson C., Robertson C., Cottrell S., Smyth B., Zambon M. Vaccine effectiveness of 2011/12 trivalent seasonal influenza vaccine in preventing laboratory-confirmed influenza in primary care in the United Kingdom: evidence of waning intra-seasonal protection. Euro Surveill. 2013, 18. pii: 20389.
27. Schulze I.T. Effects of glycosylation on the properties and functions of influenza virus hemagglutinin. J. Infect. Dis. 1997, 176:S24-S28.
28. Skehel J.J., Wiley D.C. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. Annu. Rev. Biochem. 2000, 69:531-569.
29. Skowronski D., Janjua N., De Serres G., Dickinson J., Winter A., Mahmud S., Sabaiduc S., Gubbay J., Charest H., Petric M. Interim estimates of influenza vaccine effectiveness in 2012/13 from Canada's sentinel surveillance network, January 2013. Euro Surveill. 2013, 18. pii: 20394.
30. Sun S., Wang Q., Zhao F., Chen W., Li Z. Prediction of biological functions on glycosylation site migrations in human influenza H1N1 viruses. PLoS ONE 2012, 7:e32119.
31. Tamura K., Peterson D., Peterson N., Stecher G., Nei M., Kumar S. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol. Biol. Evol. 2011, 28:2731-2739.
32. Treanor J. Influenza vaccine - outmaneuvering antigenic shift and drift. N. Engl. J. Med. 2004, 350:218-220.
33. WHO Review of the 2012-2013 winter influenza season, northern hemisphere. Wkly. Epidemiol. Rec. 2013, 88:225-232.
34. WHO WHO Recommended Surveillance Standards 2009, (cited 19.08.09.). second ed.
35. WHO Influenza Centre London. February 2012 Interim Report. Report Prepared for the WHO Annual Consultation on the Composition of Influenza Vaccine for the Northern Hemisphere. 20th-22nd February 2012 2012.
36. WHO Sequencing Primers and Protocol 2009.
37. Xu R., de Vries R.P., Zhu X., Nycholat C.M., McBride R., Yu W., Paulson J.C., Wilson I.A. Preferential recognition of avian-like receptors in human influenza A H7N9 viruses. Science 2013, 342:1230-1235.
38. Yang J.R., Huang Y.P., Lin Y.C., Su C.H., Kuo C.Y., Hsu L.C., Wu H.S., Liu M.T. Early findings of oseltamivir-resistant pandemic (H1N1) 2009 influenza A viruses in Taiwan. Antiviral Res. 2010, 88:256-262.
39. Yang X., Yao Y., Chen M., Xie Y., Liu Y., Zhao X., Gao Y., Wei L. Etiology and clinical characteristics of influenza-like illness (ILI) in outpatients in Beijing, June 2010 to May 2011. PLoS ONE 2012, 7:e28786.